Switch to:
Also traded in: Germany, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.09
MYL's Cash to Debt is ranked lower than
90% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.63 vs. MYL: 0.09 )
Ranked among companies with meaningful Cash to Debt only.
MYL' s Cash to Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.82 Max: 44.56
Current: 0.09
0.02
44.56
Equity to Asset 0.46
MYL's Equity to Asset is ranked lower than
73% of the 677 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. MYL: 0.46 )
Ranked among companies with meaningful Equity to Asset only.
MYL' s Equity to Asset Range Over the Past 10 Years
Min: 0.21  Med: 0.47 Max: 0.9
Current: 0.46
0.21
0.9
Interest Coverage 3.86
MYL's Interest Coverage is ranked lower than
86% of the 470 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 123.58 vs. MYL: 3.86 )
Ranked among companies with meaningful Interest Coverage only.
MYL' s Interest Coverage Range Over the Past 10 Years
Min: 0.83  Med: 3.59 Max: 9.19
Current: 3.86
0.83
9.19
F-Score: 7
Z-Score: 2.26
M-Score: -1.95
WACC vs ROIC
9.51%
6.61%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 14.95
MYL's Operating margin (%) is ranked higher than
69% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.82 vs. MYL: 14.95 )
Ranked among companies with meaningful Operating margin (%) only.
MYL' s Operating margin (%) Range Over the Past 10 Years
Min: 5.8  Med: 16.42 Max: 26.53
Current: 14.95
5.8
26.53
Net-margin (%) 9.41
MYL's Net-margin (%) is ranked higher than
62% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.45 vs. MYL: 9.41 )
Ranked among companies with meaningful Net-margin (%) only.
MYL' s Net-margin (%) Range Over the Past 10 Years
Min: -3.53  Med: 9.23 Max: 16.24
Current: 9.41
-3.53
16.24
ROE (%) 9.30
MYL's ROE (%) is ranked higher than
58% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. MYL: 9.30 )
Ranked among companies with meaningful ROE (%) only.
MYL' s ROE (%) Range Over the Past 10 Years
Min: -14.72  Med: 14.57 Max: 29.99
Current: 9.3
-14.72
29.99
ROA (%) 3.36
MYL's ROA (%) is ranked lower than
51% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.67 vs. MYL: 3.36 )
Ranked among companies with meaningful ROA (%) only.
MYL' s ROA (%) Range Over the Past 10 Years
Min: -2.47  Med: 5.05 Max: 10.13
Current: 3.36
-2.47
10.13
ROC (Joel Greenblatt) (%) 16.74
MYL's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.76 vs. MYL: 16.74 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MYL' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 17.9  Med: 35.11 Max: 47.2
Current: 16.74
17.9
47.2
Revenue Growth (3Y)(%) 11.60
MYL's Revenue Growth (3Y)(%) is ranked higher than
65% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. MYL: 11.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MYL' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -6.1  Med: 15.55 Max: 54.5
Current: 11.6
-6.1
54.5
EBITDA Growth (3Y)(%) 11.30
MYL's EBITDA Growth (3Y)(%) is ranked higher than
57% of the 531 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. MYL: 11.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MYL' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -20  Med: 11.85 Max: 107
Current: 11.3
-20
107
EPS Growth (3Y)(%) 24.10
MYL's EPS Growth (3Y)(%) is ranked higher than
75% of the 487 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. MYL: 24.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MYL' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -29.1  Med: 12.20 Max: 110.4
Current: 24.1
-29.1
110.4
» MYL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

MYL Guru Trades in Q1 2015

Tom Russo 5,850 sh (New)
Steven Cohen 253,300 sh (New)
Pioneer Investments 826,251 sh (+19.54%)
Vanguard Health Care Fund 15,891,898 sh (+5.68%)
Scott Black 187,570 sh (+3.18%)
Mario Gabelli 10,000 sh (unchged)
John Paulson 14,948,400 sh (unchged)
Paul Tudor Jones 125,000 sh (unchged)
Louis Moore Bacon Sold Out
Ray Dalio Sold Out
John Hussman Sold Out
First Eagle Investment 586,016 sh (-30.38%)
Paul Tudor Jones 109,447 sh (-56.94%)
Joel Greenblatt 16,021 sh (-97.62%)
» More
Q2 2015

MYL Guru Trades in Q2 2015

Jim Simons 548,006 sh (New)
Eric Mindich 1,456,404 sh (New)
Louis Moore Bacon 210,000 sh (New)
David Tepper 989,528 sh (New)
Kyle Bass 780,251 sh (New)
Larry Robbins 1,815,874 sh (New)
John Keeley 37,050 sh (New)
Steven Cohen 1,331,200 sh (+425.54%)
Mario Gabelli 33,250 sh (+232.50%)
John Paulson 21,913,061 sh (+46.59%)
Vanguard Health Care Fund 15,891,898 sh (unchged)
Tom Russo 5,850 sh (unchged)
George Soros 160,000 sh (unchged)
First Eagle Investment Sold Out
Joel Greenblatt Sold Out
Scott Black 185,573 sh (-1.06%)
Pioneer Investments 631,760 sh (-23.54%)
Paul Tudor Jones 12,766 sh (-88.34%)
» More
Q3 2015

MYL Guru Trades in Q3 2015

Jim Simons 1,716,741 sh (+213.27%)
Mario Gabelli 67,250 sh (+102.26%)
John Keeley 56,120 sh (+51.47%)
Vanguard Health Care Fund 23,262,875 sh (+46.38%)
Steven Cohen 1,000,000 sh (unchged)
John Paulson 21,913,061 sh (unchged)
Tom Russo 5,850 sh (unchged)
Eric Mindich Sold Out
Scott Black 180,575 sh (-2.69%)
Paul Tudor Jones 10,768 sh (-15.65%)
Pioneer Investments 365,302 sh (-42.18%)
Larry Robbins 934,006 sh (-48.56%)
David Tepper 470,071 sh (-52.50%)
Louis Moore Bacon 80,000 sh (-61.90%)
Steven Cohen 360,900 sh (-72.89%)
Kyle Bass 78,905 sh (-89.89%)
» More
Q4 2015

MYL Guru Trades in Q4 2015

Vanguard Health Care Fund 24,253,075 sh (+4.26%)
Mario Gabelli 26,450 sh (-60.67%)
» More
» Details

Insider Trades

Latest Guru Trades with MYL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 28.80
MYL's P/E(ttm) is ranked lower than
54% of the 753 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.84 vs. MYL: 28.80 )
Ranked among companies with meaningful P/E(ttm) only.
MYL' s P/E(ttm) Range Over the Past 10 Years
Min: 7.05  Med: 24.93 Max: 112.56
Current: 28.8
7.05
112.56
Forward P/E 9.41
MYL's Forward P/E is ranked higher than
85% of the 417 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.22 vs. MYL: 9.41 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 28.90
MYL's PE(NRI) is ranked lower than
51% of the 542 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.10 vs. MYL: 28.90 )
Ranked among companies with meaningful PE(NRI) only.
MYL' s PE(NRI) Range Over the Past 10 Years
Min: 7.05  Med: 25.32 Max: 200.11
Current: 28.9
7.05
200.11
P/B 2.54
MYL's P/B is ranked higher than
51% of the 935 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.59 vs. MYL: 2.54 )
Ranked among companies with meaningful P/B only.
MYL' s P/B Range Over the Past 10 Years
Min: 0.64  Med: 2.67 Max: 7.02
Current: 2.54
0.64
7.02
P/S 2.63
MYL's P/S is ranked lower than
53% of the 936 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.49 vs. MYL: 2.63 )
Ranked among companies with meaningful P/S only.
MYL' s P/S Range Over the Past 10 Years
Min: 0.56  Med: 2.54 Max: 6.39
Current: 2.63
0.56
6.39
PFCF 39.51
MYL's PFCF is ranked lower than
60% of the 450 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 30.49 vs. MYL: 39.51 )
Ranked among companies with meaningful PFCF only.
MYL' s PFCF Range Over the Past 10 Years
Min: 8.81  Med: 19.63 Max: 151.31
Current: 39.51
8.81
151.31
POCF 16.60
MYL's POCF is ranked higher than
64% of the 611 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.10 vs. MYL: 16.60 )
Ranked among companies with meaningful POCF only.
MYL' s POCF Range Over the Past 10 Years
Min: 6.09  Med: 12.68 Max: 40.56
Current: 16.6
6.09
40.56
EV-to-EBIT 31.76
MYL's EV-to-EBIT is ranked lower than
73% of the 774 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 18.36 vs. MYL: 31.76 )
Ranked among companies with meaningful EV-to-EBIT only.
MYL' s EV-to-EBIT Range Over the Past 10 Years
Min: -387.8  Med: 22.10 Max: 193.6
Current: 31.76
-387.8
193.6
EV-to-EBITDA 18.53
MYL's EV-to-EBITDA is ranked lower than
59% of the 821 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.09 vs. MYL: 18.53 )
Ranked among companies with meaningful EV-to-EBITDA only.
MYL' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5  Med: 14.70 Max: 42.2
Current: 18.53
5
42.2
PEG 3.54
MYL's PEG is ranked lower than
63% of the 276 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.11 vs. MYL: 3.54 )
Ranked among companies with meaningful PEG only.
MYL' s PEG Range Over the Past 10 Years
Min: 0.65  Med: 2.43 Max: 4.44
Current: 3.54
0.65
4.44
Shiller P/E 86.30
MYL's Shiller P/E is ranked lower than
75% of the 165 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 43.30 vs. MYL: 86.30 )
Ranked among companies with meaningful Shiller P/E only.
MYL' s Shiller P/E Range Over the Past 10 Years
Min: 14.33  Med: 66.33 Max: 152.12
Current: 86.3
14.33
152.12
Current Ratio 1.76
MYL's Current Ratio is ranked lower than
60% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.27 vs. MYL: 1.76 )
Ranked among companies with meaningful Current Ratio only.
MYL' s Current Ratio Range Over the Past 10 Years
Min: 1.28  Med: 3.23 Max: 8.49
Current: 1.76
1.28
8.49
Quick Ratio 1.23
MYL's Quick Ratio is ranked lower than
63% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.65 vs. MYL: 1.23 )
Ranked among companies with meaningful Quick Ratio only.
MYL' s Quick Ratio Range Over the Past 10 Years
Min: 0.85  Med: 2.69 Max: 6.76
Current: 1.23
0.85
6.76
Days Inventory 176.38
MYL's Days Inventory is ranked lower than
74% of the 643 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 118.46 vs. MYL: 176.38 )
Ranked among companies with meaningful Days Inventory only.
MYL' s Days Inventory Range Over the Past 10 Years
Min: 88.95  Med: 140.60 Max: 175.9
Current: 176.38
88.95
175.9
Days Sales Outstanding 153.45
MYL's Days Sales Outstanding is ranked lower than
86% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.01 vs. MYL: 153.45 )
Ranked among companies with meaningful Days Sales Outstanding only.
MYL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 70.32  Med: 84.21 Max: 107.26
Current: 153.45
70.32
107.26
Days Payable 119.21
MYL's Days Payable is ranked higher than
73% of the 558 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.59 vs. MYL: 119.21 )
Ranked among companies with meaningful Days Payable only.
MYL' s Days Payable Range Over the Past 10 Years
Min: 44.56  Med: 70.84 Max: 101.21
Current: 119.21
44.56
101.21

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.84
MYL's Price/Projected FCF is ranked higher than
62% of the 498 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.85 vs. MYL: 1.84 )
Ranked among companies with meaningful Price/Projected FCF only.
MYL' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.62  Med: 1.39 Max: 2.61
Current: 1.84
0.62
2.61
Price/DCF (Earnings Based) 3.68
MYL's Price/DCF (Earnings Based) is ranked lower than
72% of the 122 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. MYL: 3.68 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.42
MYL's Price/Median PS Value is ranked lower than
65% of the 851 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. MYL: 1.42 )
Ranked among companies with meaningful Price/Median PS Value only.
MYL' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.36  Med: 1.92 Max: 3.53
Current: 1.42
0.36
3.53
Price/Peter Lynch Fair Value 4.65
MYL's Price/Peter Lynch Fair Value is ranked lower than
61% of the 238 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.77 vs. MYL: 4.65 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
MYL' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.67  Med: 1.56 Max: 10.2
Current: 4.65
0.67
10.2
Earnings Yield (Greenblatt) (%) 3.12
MYL's Earnings Yield (Greenblatt) (%) is ranked higher than
51% of the 723 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. MYL: 3.12 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MYL' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.5  Med: 4.50 Max: 17.3
Current: 3.12
0.5
17.3
Forward Rate of Return (Yacktman) (%) 9.32
MYL's Forward Rate of Return (Yacktman) (%) is ranked higher than
57% of the 325 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.77 vs. MYL: 9.32 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MYL' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 3.6  Med: 7.50 Max: 34.2
Current: 9.32
3.6
34.2

More Statistics

Revenue(Mil) $9023
EPS $ 1.75
Beta1.27
Short Percentage of Float14.07%
52-Week Range $37.59 - 76.69
Shares Outstanding(Mil)491.75

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 9,650 10,823 11,300 11,918
EPS($) 4.31 4.99 5.37 5.62
EPS without NRI($) 4.31 4.99 5.37 5.62

Latest Earnings Webcast

» More Conference Calls

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:6MY.Germany, MYL1.Switzerland, 0R5P.UK,
Mylan NV was incorporated in Netherlands on July 7, 2014. The Company along with its subsidiaries is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. It also operates a research and development network that delivers a robust product pipeline. The Company operates in two segments, Generics and Specialty. The Generics segment develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as active pharmaceutical ingredients. The generic pharmaceutical business is conducted in the U.S. and Canada, Europe, the Middle East, and Africa and India, Australia, Japan, New Zealand and Brazil. The Specialty segment engages in the development and sale of branded specialty nebulized and injectable products. The Company owns or licenses a number of patents in the U.S. and other countries covering certain products and has also developed brand names and trademarks for other products. In North America, the Company markets products directly to wholesalers, distributors, retail pharmacy chains, long-term care facilities, mail order pharmacies and GPOs. It also market its generic products indirectly to independent pharmacies, managed care organizations, hospitals, nursing homes, pharmacy benefit management companies and government entities. The Company's competitors include other generic companies and branded drug companies that continue to sell or license branded pharmaceutical products after patent expirations and other statutory expirations. In the branded space, key competitors are generally other branded drug companies that compete based on its clinical characteristics and benefits.
» More Articles for NAS:MYL

Headlines

Articles On GuruFocus.com
David Einhorn Rebounds – Somewhat Feb 09 2016 
Keeley Funds Comments on Mylan N.V. Feb 03 2016 
KEELEY All Cap Value Fund Commentary - 4th Quarter 2015 Feb 03 2016 
David Einhorn Comments on Mylan Jan 19 2016 
Glenview's Larry Robbins Lowers Drug Manufacturers, Raises Providers Nov 20 2015 
Health Care Investor Larry Robbins Lowers Drug Manufacturers, Raises Providers Nov 20 2015 
John Paulson Keeps Gold, Buys Drug Manufacturers Nov 17 2015 
Vanguard Raises Stakes in Biogen, Mylan, Merck Nov 15 2015 
Keeley Funds Comments on Mylan NV Nov 03 2015 
Vanguard Health Care Fund Buys Biogen and Mylan, Cuts Pfizer Nov 02 2015 

More From Other Websites
[$$] Mylan defends $9.9bn Meda deal after shares fall Feb 11 2016
Edited Transcript of MYL earnings conference call or presentation 10-Feb-16 9:30pm GMT Feb 11 2016
Mylan Slumps on $7.2 Billion `Wealth Destroying' Meda Deal Feb 11 2016
[$$] Mylan Reaches $7.2 Billion Deal for Sweden’s Meda Feb 11 2016
[$$] Mylan Reaches $7.2 Billion Deal For Sweden's Meda Feb 10 2016
Here's why Mylan spent $9.9B on a pharma acquisition Feb 10 2016
Business Highlights Feb 10 2016
Business Highlights Feb 10 2016
Mylan to buy Swedish drugmaker Meda in $7.2 billion deal Feb 10 2016
Mylan to buy Swedish drugmaker Meda in $7.2 bln deal Feb 10 2016
Meda Wins Even When It's Losing Feb 10 2016
Mylan offers to buy Swedish pharma firm Meda for $9.9 bn Feb 10 2016
Mylan to buy Sweden's Meda AB for $7.2 billion Feb 10 2016
Mylan to buy Sweden's Meda AB for $7.2 billion Feb 10 2016
9 Big After-Hours Hot Stocks on the Move Feb 10 2016
Mylan Will Buy Meda For $9.9 Billion, Q4 Earnings Miss; Stock Dives Feb 10 2016
Mylan to acquire pharma company Meda for $9.9B Feb 10 2016
[$$] Mylan agrees to buy Sweden's Meda for $9.9bn including debt Feb 10 2016
Mylan Successfully Closes $7.2 Billion Deal for Meda Feb 10 2016
Mylan misses Street 4Q forecasts Feb 10 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK